EXELExelixis, Inc.
Is it growing?
Growing: earnings up +53% year on year and operating margin widening (+8.6 points).
Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +16% a year.
Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.
Trailing-twelve-month operating margin, 39.9% now against 31.3% a year earlier.
All from SEC EDGAR, as of Jul 3, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.
Is EXEL growing?
Exelixis, Inc.'s revenue has grown 12% a year over three years, and grown 16% a year over five, with earnings per share compounding at 84%.
Revenue growth, 3-year annual rate · Biotechnology median +21% · steady growth, ahead of inflation · compounded from trailing twelve-month revenue
- Revenue growth, 5-year rate
- +16%
Revenue growth, 5-year rate · +12% over three · growth has slowed since the five-year average
- Earnings per share, 3-year rate
- +84%
Earnings per share, 3-year rate · revenue +12% · earnings outgrew revenue: margins or the share count worked for shareholders
- Years of annual history on file
- 17
Years of annual history on file · FY2009 to FY2025, as filed
Details›
- Revenue FY2021
- $1.43B
- Revenue FY2022
- $1.61B
- Revenue FY2023
- $1.83B
- Revenue FY2024
- $2.17B
- Revenue FY2025
- $2.32B
Annual income statements as filed with the SEC.